(12) International Application Status Report

Received at International Bureau: 15 August 2018 (15.08.2018)

Information valid as of: 01 March 2019 (01.03.2019)

Report generated on: 15 July 2019 (15.07.2019)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2019/03026814 February 2019 (14.02.2019) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/EP2018/07147808 August 2018 (08.08.2018) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
17 306 059.1 (EP)09 August 2017 (09.08.2017) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
A61K 38/22 (2006.01); A61K 38/26 (2006.01); A61P 1/16 (2006.01)

(71) Applicant(s):
SANOFI [FR/FR]; 54 rue La Boétie 75008 Paris (FR) (for all designated states)

(72) Inventor(s):
KANNT, Aimo; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)
BIELOHUBY, Maximilian; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)
ELVERT, Ralf; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)
WAGNER, Michael; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)
BOSSART, Martin; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)
HAACK, Torsten; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)
KEIL, Stephanie; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)
SEIZ, Werner; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)

(74) Agent(s):
WEICKMANN & WEICKMANN PARTMBB; Postfach 860 820 81635 München (DE)

(54) Title (EN): GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS
(54) Title (FR): AGONISTES DU RÉCEPTEUR DE GLP-1/GLUCAGON DANS LE TRAITEMENT DE LA STÉATOSE HÉPATIQUE ET DE LA STÉATOHÉPATITE

(57) Abstract:
(EN): The present invention relates to the medical use of specific GLP-1 /glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.
(FR): La présente invention concerne l'utilisation médicale d'agonistes spécifiques du récepteur de GLP-1/glucagon dans la prévention et/ou le traitement d'une maladie du foie métabolique, en particulier la stéatose hépatique non alcoolique (NAFLD), notamment le foie gras non alcoolique (NAFL), la stéatohépatite non alcoolique (NASH) et/ou la fibrose hépatique associée à NAFLD.

International search report:
Received at International Bureau: 05 November 2018 (05.11.2018) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:
Chapter II demand received: 19 February 2019 (19.02.2019)

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:
Declaration of inventorship (Rules 4.17(iv) and 51bis.1(a)(iv)) for the purposes of the designation of the United States of America